Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement

Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will result in the reverse takeover of Clarmin by Cybin (the “Proposed Transaction”). In connection with the Proposed Transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (“Stifel GMP”) and Eight Capital, to raise a minimum of $14 million (US$10 million) and a maximum of $21 million (US$15 million), with a 15% agents’ option. “We are delighted by the varying strategic biotech and investment funds, merchant bankers, pharmaceutical and CPG executives, and strategic individual investors who have invested in Cybin to date,” Cybin CEO Paul Glavine said in the news release. “This is the beginning of a transformational moment in Cybin’s history and we expect to be well positioned to accelerate our strategic growth initiatives. We’re thrilled to receive the support of Stifel GMP and Eight Capital, a strong show of confidence in the long-term potential of the psychedelic sector.”

To view the full press release, visit http://ibn.fm/fjtZz

About Cybin

Cybin is a mushroom life sciences company advancing psychedelic and nutraceutical-based products. Cybin is launching psilocybin-based products in jurisdictions where the substance is not banned. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships. For more information, visit www.Cybin.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks | Leave a comment

Vivos Therapeutics, Inc. Non-Surgical, Non-Invasive, and Cost-Effective Solution, May Help Relieve OSA-Associated Healthcare Costs

  • Estimates suggest obstructive sleep apnea (“OSA”) costs the US economy $150 billion annually
  • Medicare beneficiaries with obstructive sleep apnea cost taxpayers $19,566 per year
  • Company’s oral appliances have shown to be effective in over 15,000 patients, successfully treated worldwide by approximately 1,250 trained dentists and doctors

It is estimated that obstructive sleep apnea (“OSA”) affects approximately 1 billion people worldwide, of which 54 million are Americans (http://ibn.fm/jBfMi). According to a study published by the Journal of Clinical Sleep Medicine, individuals with untreated OSA face increased health care utilization (“HCU”) and costs across all service aspects. Costs and HCU were evaluated by researchers over the period of a year leading up to the initiation of treatment. According to Emerson Wickwire, PhD, a lead author of the study, sleep disorders represent a massive economic burden on the U.S. health care system. Medicare beneficiaries with obstructive sleep apnea cost taxpayers an additional $19,566 per year. They also use more emergency, outpatient, inpatient, prescription health services, and medical services in general (http://ibn.fm/ZcFhY).

According to the American Academy of Sleep Medicine, the economic burden of undiagnosed sleep apnea is about $150 billion a year in the U.S. alone, and diagnosing and treating every patient who is suffering from the condition may generate annual savings of $100 billion (http://ibn.fm/veMVc).

Vivos Therapeutics’ proprietary Vivos System(R) has the potential to help reduce these costs significantly, being the first treatment modality for mild to moderate OSA that can potentially do away with the need for lifelong interventions. The system’s typical 18-24 month treatment time is a fraction of that of alternative treatments. Adults often experience immediate relief with potentially lasting benefits in a matter of months, with the possibility of eliminating the need for surgery (http://ibn.fm/zqmWB).

The multidisciplinary treatment protocol is comprised of comfortable and customized oral devices along with other therapies as needed. In most patient’s, the upper airway is effectively increased and enhanced over the course of treatment, which typically ranges from 18 to 24 months. The purpose is to reduce tissue obstructions causing OSA. Vivos’ technology represents the first true hope of an effective non-surgical OSA solution (http://ibn.fm/7GBpF).

Vivos Therapeutics, Inc. offers a new and superior alternative for treating obstructive sleep apnea and the company believes its technology represents the most important breakthrough in OSA treatment since CPAP (Continuous Positive Airway Pressure), which involves the use of special face or nasal masks.

Almost all commercial health insurance carriers offer reimbursement for the Vivos System and products.  Individual policies and reimbursement options will vary based on an individual’s policy. These unique oral devices are non-invasive and yet, unlike other OSA approaches, treat the underlying condition. Vivos is expanding its technology applications and is now running WIRB approved clinical trials to evaluate oral appliance therapy in pediatrics as the FDA does not currently recognize the treatment sleep disorder breathing for pediatrics with oral appliance therapy. The Vivos System treats the underlying condition for people of all ages.

Vivos Therapeutics is an emerging global leader in the treatment of OSA. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages breathe and sleep properly.

Trained dentists use the Vivos System to treat the conditions associated with SDB and OSA. The company is rapidly expanding the use of the Vivos System by involving dentists earlier and more actively in the process of diagnosing and treating OSA.  In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia.  The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,250 trained dentists.

For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Vivos Therapeutics Inc. | Leave a comment

SRAX Inc. (NASDAQ: SRAX) Creating Valuable Trove of Specialized Data Across 25,000 Unique Points of Segmentation

  • SRAX derives consumer data from BIGtoken platform that compensates over 16 million users from more than 30 countries for access to their data
  • BIGtoken provides brands with ability to target and access specific niche groups across 25,000 unique points of segmentation

The business of big data is evolving to benefit both consumers and marketers as demonstrated by the success of SRAX (NASDAQ: SRAX), a technology company focused on digital marketing and consumer data management. The Company’s BIGtoken platform compensates over 16 million users with cash or gift cards when they opt in to give access to their data while concurrently creating valuable data sets that can be accessed by marketers for a fee.

“Big marketers are really interested in this,” said SRAX CEO and founder Christopher Miglino in an interview on the LA Weekly Podcast with Brian Calle (http://ibn.fm/dIMJd). “They don’t want to buy bad data anymore. They want to buy data from consumers that have said ‘yes, you have the right to market to me’, so we’ve found ourselves in a unique spot.”

SRAX’s tools deliver a digital competitive advantage for companies in several verticals that include consumer goods, investor relations, luxury, and lifestyle. The Company’s technology unlocks data to reveal brands’ core consumers and their characteristics across several marketing channels by integrating all aspects of the advertising experience into a single platform. Besides giving access to marketers for a fee, SRAX also engages in the sale of specialized data sets across several verticals.

“Our primary focus is figuring out ways to monetize different data sets. We had a business a few years ago where we aggregated data on doctors in the country and then we sold that data,” said Miglinio, referring to SRAX’s healthcare vertical, SRAX MD, that sold for a $43.5 million consideration while allowing SRAX to retain a 31% ownership.

Investor relations is another key area for SRAX that has increased in importance during these unprecedented economic times, elevating demand for virtual investor relations platforms. Through SRAX’s Sequire platform, CEOs & CFOs of publicly traded companies are now able to monitor the trading behaviors of their investors while the investors in turn are kept informed on corporate prospects.

The power of big data to meet the demands of the increasingly demanding and competitive economic landscape is exemplified by SRAX’s services that give clients the ability to target and access specific niche groups across 25,000 unique points of segmentation. The platform’s unique interface gives users the power to submit specialized queries that include location and purchase history.

Besides serving clients on both sides of the data trade, SRAX also gives back to the community by allowing BIGtoken users to donate their earnings to charity through its partnerships with several high-profile, nonprofit associations. Through the program, BIGtoken users are able to support efforts put forward by the American Heart Association, HealthCorps and The ALS Association.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Jerrick Media Holdings Inc.’s (JMDA) Newly Appointed CFO to Present at Shareholder Meeting

Jerrick Media Holdings (OTCQB: JMDA), a technology company and the parent company of Vocal, recently announced the appointment of three new executives to its leadership team, including Chelsea Pullano as chief financial officer (“CFO”), effective immediately. A six year veteran of the firm, Pullano will address attendees and provide an insightful and unique presentation at next week’s shareholder meeting. The meeting is scheduled to take place at 4:30 p.m. Eastern Time on Wednesday, July 8, 2020. Interested parties are reminded to pre-register at http://ibn.fm/05uPQ.

For more information, visit https://Jerrick.media.

About Jerrick

Jerrick Media Holdings, Inc. is the parent company and creator of the Vocal platform. The Company creates technology-based solutions to solve problems for the creative community. Through Vocal, Jerrick identifies and leverages opportunities within the digital platform and content monetization space. Since launching in 2016, Vocal has become home to over 600,000 content creators and brands of all shapes and sizes, attracting audiences across its network of wholly owned and operated communities.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Closes $13M Private Placement

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, on Tuesday announced the closing of its previously disclosed $13 million private placement of senior secured convertible debentures at a fixed conversion price of $2.69. The Company received $9.1 million in net proceeds from the offering after deducting placement agent and legal fees, the repayment of loans and other estimated expenses. SRAX intends to use the proceeds to fund the rapid expansion of its investor intelligence, data analytics and communications platform, Sequire, as well as to pay back a $2.5 million outstanding secured term loan and other outstanding obligations.

To view the full press release, visit http://ibn.fm/JHD0H

About SRAX

SRAX (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data for brands in the CPG, investor relations, luxury, and lifestyle verticals. Through its various platforms, SRAX is monetizing its data sets and growing multiple recurring revenue streams. BIGtoken is a consumer-managed data marketplace where people can own and earn from their data. The platform also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. Sequire is a premier platform for investor intelligence and communication. Through Sequire, public companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX and its verticals, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Recognized for Big Data in Advertising at SBR’s Technology Excellence Awards 2020

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that it has been named winner of the Big Data Award in the advertising category at Singapore Business Review’s (“SBR”) second Technology Excellence Awards 2020. Held annually by SBR, a leading business magazine serving Singapore’s dynamic business community, the Technology Excellence Awards recognize outstanding companies worldwide that have made exceptional contributions in pursuit of technological innovation. “We are thrilled to receive this award from Singapore Business Review which further recognizes iClick’s leadership in the international digital marketing industry,” Jian “T.J.” Tang, iClick’s CEO and co-founder, stated in the news release. “Drawing on our cutting-edge technologies and robust data resources, iClick will persist in our mission to relentlessly develop and upgrade our intelligent marketing solutions to help global clients build presence and successfully fuel growth in China with the best and the most efficient data-driven, one-stop marketing solutions, as we continue our evolution into a fully integrated marketing and enterprise cloud platform.”

To view the full press release, visit http://ibn.fm/V4hQp

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, its proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in iClick Interactive Asia Group Ltd. ICLK, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) and Leica Microsystems Collaborate to Offer Innovative Combined Workflow Expected to Accelerate Cancer R&D

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries, today announced its entry into a worldwide co-marketing agreement with German-based Leica Microsystems CMS GmbH, a Danaher company. Per the update, the historic alliance is expected to offer transformative new empowerment to cancer research worldwide through integrating the latest enabling technologies in capturing, isolating and preparing biopsy samples for superior analysis of relevant biomarkers of disease state and treatment response. “The generation of reliable and reproducible data from biopsy samples is difficult, as it requires the integration of multiple and varied laboratory processes, particularly tissue extraction, sample preparation, and analysis,” Roxana McCloskey, PBI’s Global Director of Sales & Marketing, stated in the news release. “The innovative LMD-PCT workflow enables the reproducible and rapid extraction of proteins from precious clinical samples by combining the precision of the Leica LMD system with PBI’s versatile PCT sample preparation platform. The ability to co-market the workflow offers the opportunity for the combined sales and marketing forces of Leica and PBI to extend the integrated LMD-PCT systems into additional research centers globally that are focused on clinical proteomics, cancer research, biomarker discovery, and precision medicine.”

To view the full press release, visit http://ibn.fm/WdQ4H

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $2.2M Through Warrant Exercise

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday announced the closing of its previously announced transaction. According to the update, Predictive Oncology secured approximately $2.2 million in gross cash proceeds from the transaction, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock, each at an exercise price of $1.575. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1 (File No. 333-239207). The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

To view the full press release, visit http://ibn.fm/40gIG

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRTC) Secures New Follow-On Order for Major Police Force

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced its receipt of a new follow-on order for 21,600 additional BolaWrap cartridges for the Indonesia National Police force. The Company previously reported the fulfillment of an initial order of devices and cartridges placed by its distributor in Indonesia at the end of 2019. Following successful BolaWrap demonstrations across the country, the Company’s distributor recently secured a contract with the Indonesian National Police force. “We are very pleased to see both new international orders and follow-on orders such as this one for a major police force,” Tom Smith, president at Wrap Technologies, stated in the news release. “We believe this order reflects the Indonesian National Police force’s acceptance of the BolaWrap as a viable solution to an age-old challenge in policing – safely detaining noncompliant subjects without injury.”

To view the full press release, visit http://ibn.fm/I85ec

About Wrap Technologies (NASDAQ: WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.WrapTechnologies.com. Examples of recent media coverage are available as links under the “Media” tab of the website.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Wrap Technologies Inc. WRTC | Leave a comment

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) Announces Strategic Expansion of Leadership Team

Jerrick Media Holdings (OTCQB: JMDA), a technology company and the parent company of Vocal, today announced the appointment of three new executives to its leadership team. According to the update, the Company named Chelsea Pullano as chief financial officer (“CFO”), effective immediately. In addition, upon Jerrick’s planned NASDAQ uplisting this summer, Danielle Banner will be formally named chief revenue officer (“CRO”) and Robby Tal as chief strategy officer (“CSO”). “As we head into our shareholder meeting, we have assembled the right team to manage our transition from the OTCQB to the NASDAQ Capital Markets,” Jerrick’s president and Head of Product Justin Maury stated in the news release. “With the combined strength of our employees as a whole, and with Officers of the high caliber that Chelsea, Danielle, and Robby represent, our team represents the ideal collective to execute on both our product expansion and our corporate vision.”

To view the full press release, visit http://ibn.fm/Jvly9

About Jerrick

Jerrick Media Holdings, Inc. is the parent company and creator of the Vocal platform. The Company creates technology-based solutions to solve problems for the creative community. Through Vocal, Jerrick identifies and leverages opportunities within the digital platform and content monetization space. Since launching in 2016, Vocal has become home to over 600,000 content creators and brands of all shapes and sizes, attracting audiences across its network of wholly owned and operated communities. For more information, visit the Company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Jerrick Media Holdings Inc. JMDA, MissionIRNewsBreaks | Leave a comment